000403 Stock Overview
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Pacific Shuanglin Bio-pharmacy Co., LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.66 |
| 52 Week High | CN¥31.25 |
| 52 Week Low | CN¥17.49 |
| Beta | 0.43 |
| 11 Month Change | -3.58% |
| 3 Month Change | -7.94% |
| 1 Year Change | 33.57% |
| 33 Year Change | -13.55% |
| 5 Year Change | n/a |
| Change since IPO | -30.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000403 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -3.6% | -2.2% |
| 1Y | 33.6% | -23.4% | -17.9% |
Return vs Industry: 000403 exceeded the CN Biotechs industry which returned -23.4% over the past year.
Return vs Market: 000403 exceeded the CN Market which returned -17.9% over the past year.
Price Volatility
| 000403 volatility | |
|---|---|
| 000403 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000403 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000403's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,426 | n/a | www.slbiop.com |
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation.
Pacific Shuanglin Bio-pharmacy Co., LTD Fundamentals Summary
| 000403 fundamental statistics | |
|---|---|
| Market cap | CN¥19.49b |
| Earnings (TTM) | CN¥677.68m |
| Revenue (TTM) | CN¥2.50b |
28.8x
P/E Ratio7.8x
P/S RatioIs 000403 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000403 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.50b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥1.30b |
| Other Expenses | CN¥618.88m |
| Earnings | CN¥677.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | 0.93 |
| Gross Margin | 51.79% |
| Net Profit Margin | 27.07% |
| Debt/Equity Ratio | 7.0% |
How did 000403 perform over the long term?
See historical performance and comparison